Allergy & Immunology
Exceedingly rare side effects reported with AstraZeneca vaccine in the UK – 22 cases of cerebral venous sinus thrombosis with low levels of platelets out of 18 million vaccinated individuals
5 Apr, 2021 | 01:45h | UTCCovid-19: Seven UK blood clot deaths after AstraZeneca vaccine – BBC
Original report: Coronavirus vaccine – weekly summary of Yellow Card reporting – Medicines and Healthcare products Regulatory Agency
Related opinion: Undermining the AstraZeneca jab is a dangerous act of political folly – The Guardian
“Based on current experience, the expected benefits of both COVID-19 vaccines in preventing COVID-19 and its serious complications far outweigh any known side effects”
RCT: Upadacitinib vs. Adalimumab for Psoriatic Arthritis
5 Apr, 2021 | 00:57h | UTCTrial of Upadacitinib and Adalimumab for Psoriatic Arthritis – New England Journal of Medicine (link to abstract – $ for full-text)
RCT: Efficacy and safety of a dexamethasone intracanalicular insert in patients with allergic conjunctivitis
5 Apr, 2021 | 00:54h | UTCPhase 3 Randomized Study of Efficacy and Safety of a Dexamethasone Intracanalicular Insert in Patients With Allergic Conjunctivitis – American Journal of Ophthalmology (link to abstract – $ for full-text)
Video: Why you can’t compare Covid-19 vaccines
2 Apr, 2021 | 09:33h | UTCWhy you can’t compare Covid-19 vaccines – Vox
Why is it so hard to investigate the rare side effects of COVID vaccines?
2 Apr, 2021 | 09:28h | UTCWhy is it so hard to investigate the rare side effects of COVID vaccines? – Nature
[Press release – not published yet] Pfizer/BioNTech vaccine is 91% effective for at least 6 months
2 Apr, 2021 | 09:29h | UTCCommentaries: Ongoing trial shows Pfizer Covid-19 vaccine remains highly effective after six months – CNN AND Coronavirus: Pfizer jab ‘stopping 91% of cases in first six months’ – BBC AND Expert reaction to press release from Pfizer and BioNTech on efficacy and safety up to six months after second vaccine dose, including data from South Africa – Science Media Centre AND Pfizer’s COVID-19 vaccine effective after 6 months and works against problem variant – LiveScience
Another study shows a single dose of mRNA vaccine may be enough for patients with previous Covid-19
2 Apr, 2021 | 09:36h | UTCCommentary: If I’ve Had COVID-19, Do I Still Need Two Doses of Vaccine? – TIME AND The research is in: People who’ve already had COVID-19 need just one shot – Insider
Related: Studies: Single dose of vaccine acts as ‘booster’ in those with prior COVID-19 infection (studies and commentary) AND Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2 – JAMA AND Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine – New England Journal of Medicine
AstraZeneca COVID vaccine 70% effective vs. B117 variant
1 Apr, 2021 | 03:55h | UTCAstraZeneca COVID vaccine 70% effective vs B117 variant – CIDRAP
Commentary on Twitter (thread – Click for more)
ASYMPTOMATIC & SYMPTOMATIC Efficacy of Oxford-AstraZeneca #COVID19 vaccine versus #B117 & non-B117 variants via 200k swabs in ~8500:🧵
Symptomatic #B117➡️ 70%
Asymptomatic #B117➡️ 29%
Other variants symptomatic➡️ 81.5%
Other variants asymptomatic➡️ 70%https://t.co/qSWYlHKP0g pic.twitter.com/gS7P9MCpyz
— Eric Feigl-Ding (@DrEricDing) March 31, 2021
Antibody evasion by the P.1 strain of SARS-CoV-2
31 Mar, 2021 | 03:36h | UTCAntibody evasion by the P.1 strain of SARS-CoV-2 – Cell
Commentary on Twitter (thread – Click for more)
An in-depth assessment of the P.1 (Brazil) variant
—less immune evasion than B.1.351 (South Africa) variant despite similar receptor binding domain mutations
—very good neutralization by mRNA vaccine via sera from vaccineshttps://t.co/2m0A1Pjs9O @CellCellPress today pic.twitter.com/uyV2eZdLQ9— Eric Topol (@EricTopol) March 30, 2021
[Preprint] Single dose of AstraZeneca and Pfizer vaccines shows 62% efficacy for preventing disease and reduces viral load/transmissibility of SARS-CoV-2 in residents of Long-Term Care Facilities
31 Mar, 2021 | 03:38h | UTCCommentaries: Single dose of Pfizer and Oxford vaccines shows 60% efficacy in elderly care home residents – NewsMedical AND Care home residents gain 62% protection from single dose of COVID-19 vaccine – University College London
Commentary on Twitter (thread – click for more)
https://twitter.com/sailorrooscout/status/1376512132318121990
Another study indicates SARS-CoV-2 variant B.1.351, but not variant B.1.1.7, has partial resistance to neutralizing antibodies generated by natural infection or mRNA vaccination
28 Mar, 2021 | 22:53h | UTC
Commentaries on Twitter
Now a peer-reviewed pub in a top journal, this elegant study clearly shows that variant B.1.351 isn't stopped by antibodies from prior infection or the Pfizer vax. We'll have revised vaccines, but we don't yet. Please behave accordingly. https://t.co/w8GHPDB7aL
— EQV Analytics 🇺🇦😷🔬🪷 (@AnalyticsEqv) March 27, 2021
New @NatureMedicine, further data on immune response after vaccination to 2 variants, B.1.1.7 (UK) and B.1.351 (SA). Reinforcing recent reports, the latter is more of an immune evader, and may pose vulnerability for reinfection post-vaccinehttps://t.co/w8xFc3fkh5 pic.twitter.com/i7DAnjSZwE
— Eric Topol (@EricTopol) March 26, 2021
RCT: Abrocitinib vs. Placebo or Dupilumab for Atopic Dermatitis
26 Mar, 2021 | 08:27h | UTCAbrocitinib versus Placebo or Dupilumab for Atopic Dermatitis – New England Journal of Medicine
Pfizer coronavirus vaccine found to be moderately less effective against B.1.351 variant
24 Mar, 2021 | 08:35h | UTCNews release: Pfizer vaccine less effective against South African variant, study finds – Ben-Gurion University of the Negev
Commentary on Twitter
SARS-CoV-2 variants & neutralization: @RanTaube &Co assess #SARSCoV2 neutralization activity of convalescent or Pfizer-vaccinee sera. While vaccinee sera comparably neutralizes WT& B.1.1.7 pseudoviruses, B.1.351 moderately resists vaccine neutralization https://t.co/wucbeLY075 pic.twitter.com/B1y7vFsMDL
— Cell Host & Microbe (@cellhostmicrobe) March 22, 2021
M-A: Most patients with allergy to Penicillin can be given Cefazolin
21 Mar, 2021 | 21:41h | UTC
Commentary on Twitter (thread – click for more)
1/Returning to my first love #antibioticallergy #penicillin allergy with @PharmerMeg to announce to #IDtwitter #MedTwitter that if you see a patient with a "penicillin allergy" history, the likelihood of them having a reaction to cefazolin/ancef is 0.7%. https://t.co/czVX6wik2Y
— Kimberly Blumenthal, MD, MSc (@KimberlyBlumen1) March 17, 2021
[Press release – not published yet] AstraZeneca vaccine 79% effective for preventing symptomatic COVID-19
23 Mar, 2021 | 02:36h | UTCCommentaries: AstraZeneca vaccine is 79% effective against symptomatic Covid-19, company says – CNN AND AstraZeneca’s Covid-19 vaccine shows better-than-expected efficacy in U.S. trial – STAT AND Expert reaction to press release from AstraZeneca announcing interim data on safety and efficacy from the US trial of the Oxford-AstraZeneca COVID-19 vaccine – Science Media Centre AND AstraZeneca Publishes Reassuring Trial Data, But Vaccine Hesitancy Remains Widespread In European Union – Health Policy Watch
Review | Post-acute COVID-19 syndrome
23 Mar, 2021 | 02:26h | UTCPost-acute COVID-19 syndrome – Nature Medicine
News Release: Study underscores need for multidisciplinary care for COVID-19 long-haulers – Dana-Farber Cancer Institute
Infection and mRNA vaccine-induced immunity may be retained against SARS-CoV-2 variant B.1.1.7
21 Mar, 2021 | 22:04h | UTCNeutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination – JAMA
SARS-CoV-2 variants B.1.351 and P.1 can escape from therapeutic antibodies and evade antibodies induced by infection or mRNA vaccination
21 Mar, 2021 | 22:02h | UTCSARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies – Cell
[Preprint] Oxford/AstraZeneca and Pfizer/BioNTech vaccines probably can still neutralize P.1 strain of SARS-CoV-2, but at lower levels
21 Mar, 2021 | 21:55h | UTCAntibody evasion by the Brazilian P.1 strain of SARS-CoV-2 – bioRxiv
Commentary: Existing COVID vaccines may protect against Brazilian variant – Oxford study – Reuters
B.1.351 strain of SARS-CoV-2 neutralization titer reduced 8- to 9-fold for Pfizer and AstraZeneca vaccinees. Convalescent plasma and therapeutic antibodies were less effective against this variant as well.
21 Mar, 2021 | 21:52h | UTCEvidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera – Cell
Perspective | Five reasons why COVID herd immunity is probably impossible
19 Mar, 2021 | 08:19h | UTCFive reasons why COVID herd immunity is probably impossible – Nature
Systematic Review: Biologics for chronic rhinosinusitis
18 Mar, 2021 | 08:44h | UTCBiologics for chronic rhinosinusitis – Cochrane Library
Opinion | “’It’s a very special picture.’ Why vaccine safety experts put the brakes on AstraZeneca’s COVID-19 vaccine”
18 Mar, 2021 | 09:14h | UTC‘It’s a very special picture.’ Why vaccine safety experts put the brakes on AstraZeneca’s COVID-19 vaccine – Science (a few articles per month are free)
Related: Update on the safety of COVID-19 Vaccine AstraZeneca (statement and commentaries)
WHO Statement | The benefits of the AstraZeneca vaccine outweigh its risks – vaccinations should continue
18 Mar, 2021 | 09:17h | UTCWHO statement on AstraZeneca COVID-19 vaccine safety signals – World Health Organization
Related: Update on the safety of COVID-19 Vaccine AstraZeneca (statement and commentaries)
Commentary on Twitter (thread – click for more)
At this time, WHO considers that the benefits of the AstraZeneca vaccine outweigh its risks and recommends that vaccinations continue.
Full statement on AstraZeneca #COVID19 vaccine safety signals:
👉 https://t.co/9J6MtxXWK8 pic.twitter.com/fWGzqbjMuE— World Health Organization (WHO) (@WHO) March 17, 2021
Opinion | “The zero-risk mentality stifling Europe is now killing its people”
18 Mar, 2021 | 09:11h | UTCThe zero-risk mentality stifling Europe is now killing its people – The Sidney Morning Herald
Related: Update on the safety of COVID-19 Vaccine AstraZeneca (statement and commentaries)